Oregon is currently home to 1212 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Portland, Eugene, Medford and Clackamas. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)
NCT05546580
Recruiting
Iadademstat is being studied as a treatment for subjects with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with FMS-like tyrosine kinase mutation (FLT3 mut+). During the trial, iadademstat will be given in combination with gilteritinib, a drug that is already approved to treat patients with FLT3-mutated R/R AML.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/26/2024
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Register for Updates
Defining Treatment Outcomes and Genetic Architecture in Idiopathic Toe Walking*
NCT06305689
Recruiting
To compare and contrast the clinical, gait and parent-reported outcomes following either non-operative (casting) or operative treatment for children with idiopathic toe walking (ITW) and determine whether there are specific genes associated with ITW.
Gender:
ALL
Ages:
Between 6 years and 18 years
Trial Updated:
07/23/2024
Locations: Shriners Hospitals for Children, Portland, Oregon
Conditions: Idiopathic Toe Walking
Register for Updates
Patterned Multichannel Vibrotactile Stimulation for the Longitudinal Treatment of Moderate Stage Parkinson's Disease
NCT05830110
Recruiting
The purpose of the present research is to examine the effectiveness of a non-invasive, vibrotactile stimulation protocol, known as coordinated reset (CR), for the alleviation of motor symptoms in patients with Parkinson's disease (PD). PD patients exhibit rigidity, slowness (bradykinesia) and poverty (akinesia) of movement as well as other symptoms. Treatment for PD is either pharmacological (first line) or invasive deep brain stimulation. The non-invasive, vibrotactile stimulation approach uses... Read More
Gender:
ALL
Ages:
Between 45 years and 90 years
Trial Updated:
07/23/2024
Locations: Synergic Medical Technologies, Eugene, Oregon
Conditions: Parkinson's Disease
Register for Updates
MYLUNG Consortium Part 3: Observational Study
NCT05885698
Recruiting
This longitudinal study looks to quantify the testing timeline, operational barriers, and outcomes of biomarker-guided therapy in a large, community-based, and largely unselected patient population with early stage and advanced stage, treatment-naive non-small cell lung cancer, whether squamous or non-squamous.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2024
Locations: Willamette Valley Cancer Institute and Research Center, Eugene, Oregon
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Mechanisms of Risky Alcohol Use in Young Adults: Linking Sleep to Reward- and Stress-Related Brain Function
NCT05684094
Recruiting
This research will use biobehavioral approaches to generate understanding about the linkages between stressful life events, sleep duration and timing, and alcohol use in young adults, with a long-term aim of developing effective preventative interventions for alcohol use disorders.
Gender:
ALL
Ages:
Between 18 years and 24 years
Trial Updated:
07/17/2024
Locations: Oregon Sleep Lab, Eugene, Oregon
Conditions: Alcohol Use Disorder
Register for Updates
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
NCT04198766
Recruiting
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp \& Dohme LLC, a subsidiary of Merck \& Co., Inc., Rahway, NJ, USA.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2024
Locations: Providence Portland Medical Center, Portland, Oregon
Conditions: Solid Tumor, Non-Small Cell Lung Cancer, Melanoma, Head and Neck Cancer, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma
Register for Updates
Garden-fresh Foods and Gut Microbiomes
NCT06506786
Recruiting
The purpose of this research is to explore what types of microbes are present on garden-fresh versus store-bought fruits and vegetables, as well as how they might affect the human gut microbiome.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
07/16/2024
Locations: Institute for Health in the Built Environment, University of Oregon, Eugene, Oregon
Conditions: Gut Microbiome
Register for Updates
Sex Differences in Trauma, Inflammation and Brain Function and the Implications for Treatment Efficacy in Alcohol Use Disorder
NCT06426303
Recruiting
The goal of this clinical trial is to identify sex-specific biomarkers that confer greater susceptibility for Alcohol Use Disorder (AUD) and differentiate how treatment response varies by sex in people with Alcohol Use Disorder. The main questions it aims to answer are: * How does trauma affect emotion regulation, inflammation, and limbic function, and what are the sex-dependent effects of NTX (Naltrexone) on these aspects? * What is the mechanism of Naltrexone (NTX), and how does it potential... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
07/16/2024
Locations: VA Portland Health Care System, Portland, Oregon
Conditions: Alcohol Use Disorder
Register for Updates
COMmunity of Practice And Safety Support for Navigating Pain (COMPASS-NP)
NCT05492903
Recruiting
Home care workers (HCWs) are at-risk for chronic pain and associated problems, including emotional distress, opioid use and misuse, and work-related disability. To address these issues, the proposed study will adapt an established peer-led and supportive group program to address the needs of HCWs with chronic pain. The new program, named COMPASS for Navigating Pain (COMPASS-NP), will integrate work-based injury protections with pain education and cognitive-behavioral therapy strategies for pain... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2024
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Pain Management, Ergonomics, Wounds and Injuries
Register for Updates
Essential Amino Acid Supplementation for Femoral Fragility Fractures
NCT06050668
Recruiting
This trial will evaluate the impact of 4 weeks of postoperative essential amino acid (EAA)-based supplementation on muscle morphology after femoral fragility fracture. This trial will assess the ability of EAA-based to increase skeletal muscle metabolic activity, reduce inflammation, and induce muscle fiber hypertrophy, as well as preserve skeletal muscle mass and physical performance up to 6 months after injury. Participants will be randomized in a 1:1 ratio to 1) standard of care (no dietary i... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/15/2024
Locations: Slocum Center for Orthopedics & Sports Medicine, Eugene, Oregon
Conditions: Femoral Fracture, Fragility Fracture, Muscle Atrophy
Register for Updates
A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia
NCT05785819
Recruiting
The purpose of this study is to evaluate the efficacy and safety of VLX-1005, a 12-lipoxygenase (12-LOX) enzyme inhibitor in treating heparin induced thrombocytopenia (HIT). Participants with suspected HIT will receive the usual standard of care, and will be assigned randomly to either VLX-1005 or placebo treatment. The study will measure important outcomes including platelet count, stroke, pulmonary embolus (clot to the lungs) and bleeding.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/12/2024
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Thrombocytopenia, Immune, Heparin Induced Thrombocytopenia
Register for Updates
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
NCT02735707
Recruiting
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia. In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic such as COVID-19. REMAP-COVID is a sub-platform of REMAP-CAP th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2024
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Community-acquired Pneumonia, Influenza, COVID-19
Register for Updates